About this trial
The TURK CTO Registry is a prospective, multicenter, observational registry designed to evaluate the contemporary management and outcomes of percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) in Türkiye.
The registry will include consecutive adult patients undergoing CTO PCI at participating centers. Detailed data on patient characteristics, cardiovascular risk factors, lesion and procedural characteristics, CTO crossing strategies, guidewires and devices, procedural techniques, radiation exposure, contrast use, procedural success, and in-hospital complications will be collected using a standardized electronic data collection system.
The primary objective of the registry is to characterize contemporary CTO PCI practice in Türkiye and to evaluate procedural success and safety. Secondary objectives include identifying clinical, angiographic, and procedural factors associated with technical and procedural success, complications, resource utilization, and patient outcomes.
The registry is expected to provide real-world, multicenter data on CTO PCI practice and to help identify factors associated with successful and safe CTO revascularization in Türkiye. No treatment or procedural strategy will be assigned by the study protocol; all clinical and procedural decisions will be made by the treating physicians according to routine clinical practice.
Eligibility criteria
Qualifiers
Age ≥18 years
Presence of at least one coronary chronic total occlusion (CTO), defined as a coronary artery lesion with TIMI grade 0 antegrade flow and an estimated duration of occlusion of ≥3 months
Undergoing an attempted PCI of the CTO at a participating center during the study period
Provision of informed consent when required by the applicable ethics committee and local regulations
Disqualifiers
Age <18 years
Coronary lesion not meeting the predefined criteria for CTO
No attempted CTO PCI during the procedure
Inability or refusal to provide informed consent when informed consent is required
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Ahmet Seyfeddin Gürbüz
Lead sponsor
Necmettin Erbakan University
Sponsor institution